The DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.
Complex Interplay between the P-Glycoprotein Multidrug Efflux Pump and the Membrane: Its Role in Modulating Protein Function
Open accessAbstract
Multidrug resistance in cancer is linked to expression of the P-glycoprotein multidrug transporter (Pgp, ABCB1), which exports many structurally diverse compounds from cells. Substrates first partition into the bilayer and then interact with a large flexible binding pocket within the transporter's transmembrane regions. Pgp has been described as a hydrophobic vacuum cleaner or an outwardly directed drug/lipid flippase. Recent X-ray crystal structures have shed some light on the nature of the drug-binding pocket and suggested routes by which substrates can enter it from the membrane. Detergents have profound effects on Pgp function, and several appear to be substrates. Biochemical and biophysical studies in vitro, some using purified reconstituted protein, have explored the effects of the membrane environment. They have demonstrated that Pgp is involved in a complex relationship with its lipid environment, which modulates the behavior of its substrates, as well as various functions of the protein, including ATP hydrolysis, drug binding, and drug transport. Membrane lipid composition and fluidity, phospholipid headgroup and acyl chain length all influence Pgp function. Recent studies focusing on thermodynamics and kinetics have revealed some important principles governing Pgp-lipid and substrate-lipid interactions, and how these affect drug-binding and transport. In some cells, Pgp is associated with cholesterol-rich microdomains, which may modulate its functions. The relationship between Pgp and cholesterol remains an open question; however, it clearly affects several aspects of its function in addition to substrate-membrane partitioning. The action of Pgp modulators appears to depend on their membrane permeability, and membrane fluidizers and surfactants reverse drug resistance, likely via an indirect mechanism. A detailed understanding of how the membrane affects Pgp substrates and Pgp's catalytic cycle may lead to new strategies to combat clinical drug resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Ruetz, S., Brault, M., Dalton, W. S., & Gros, P. (1999) · Biochemistry · doi:10.1021/bi995067h · Cited by 23
Retracted(1996) · Institutional Research Information System University of Turin (University of Turin) · doi:10.1111/j · Cited by 5,486
Evidence for the Formation of Symmetric and Asymmetric DLPC-DAPC Lipid Bilayer Domains
Ritter, M., Schmidt, S., Jakab, M., Paulmichl, M., & Henderson, R. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350122 · Cited by 3,923
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609 · cited 2×
“Three different strategies for defeating Pgp have been described (1); “engage” (co-administration of anti-cancer drugs and modulators), “evade” (the use of anti-cancer drugs that are poor Pgp substrates), and “exploit” (specific targeting of the Pgp molecule).”
BackgroundJournal of Biological Chemistry
(2021) · Journal of Biological Chemistry · doi:10.1074/jbc · Cited by 3,400
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
FUNCTIONS OF LIPID RAFTS IN BIOLOGICAL MEMBRANES
Brown, D. A., & London, E. (1998) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.14.1.111 · Cited by 2,948
BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER
Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., & Gottesman, M. M. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.361 · Cited by 2,059
Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
Aller, S. G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., Harrell, P. M., Trinh, Y. T., Zhang, Q., Urbatsch, I. L., et al. (2009) · Science · doi:10.1126/science.1168750 · Cited by 1,929
ABC Multidrug Transporters: Structure, Function and Role in Chemoresistance
Sharom, F. J. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.1.105 · Cited by 973
Self-citation
Cited by
Emerging Diversity in Lipid–Protein Interactions
Corradi, V., Sejdiu, B. I., Mesa-Galloso, H., Abdizadeh, H., Noskov, S. Y., Marrink, S. J., & Tieleman, D. P. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00451 · Cited by 459
Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment: Miniperspective
Waghray, D., & Zhang, Q. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01457 · Cited by 400
Cell membrane modulation as adjuvant in cancer therapy
Zalba, S., & ten Hagen, T. L. M. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.10.008 · Cited by 365
Lipid–Protein Interactions Are Unique Fingerprints for Membrane Proteins
Corradi, V., Mendez-Villuendas, E., Ingólfsson, H. I., Gu, R.-X., Siuda, I., Melo, M. N., Moussatova, A., DeGagné, L. J., Sejdiu, B. I., Singh, G., et al. (2018) · ACS Central Science · doi:10.1021/acscentsci.8b00143 · Cited by 358
Phospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targets
Kopecka, J., Trouillas, P., Gašparović, A. Č., Gazzano, E., Assaraf, Y. G., & Riganti, C. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100670 · Cited by 291
Enkavi, G., Javanainen, M., Kulig, W., Róg, T., & Vattulainen, I. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00538 · Cited by 289
Jeong, C.-B., Kang, H.-M., Lee, Y. H., Kim, M.-S., Lee, J.-S., Seo, J. S., Wang, M., & Lee, J.-S. (2018) · Environmental Science & Technology · doi:10.1021/acs.est.8b03211 · Cited by 263
Hladky, S. B., & Barrand, M. A. (2018) · Fluids and Barriers of the CNS · doi:10.1186/s12987-018-0113-6 · Cited by 206
Genovese, I., Ilari, A., Assaraf, Y. G., Fazi, F., & Colotti, G. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.10.003 · Cited by 156
Comparison of mechanistic transport cycle models of ABC exporters
Szöllősi, D., Rose-Sperling, D., Hellmich, U. A., & Stockner, T. (2018) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2017.10.028 · Cited by 107
Lipid-Dependent Alternating Access Mechanism of a Bacterial Multidrug ABC Exporter
Immadisetty, K., Hettige, J., & Moradi, M. (2019) · ACS Central Science · doi:10.1021/acscentsci.8b00480 · Cited by 38
Celestino, A. T., Levy, D., Maria Ruiz, J. L., & Bydlowski, S. P. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.01.045 · Cited by 19
Dorninger, F., Vaz, F. M., Waterham, H. R., Klinken, J. B. V., Zeitler, G., Forss-Petter, S., Berger, J., & Wiesinger, C. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.08.006 · Cited by 12
Metadata
- Authors
- Sharom, F. J.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2014
- Volume
- 4
- Pages
- 41-41
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2053652959
- Cited by
- 278
- References
- 143
- FWCI
- 12.21
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.